The Respiratory Syncytial Virus Prophylactic Market is Expected to Show Static Growth during the Forecast Period

Wednesday 18 April 2012, Amsterdam

The “Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019” report is an essential source of information and analysis on the global Respiratory Syncytial Virus (RSV) Prophylactic market. The report identifies the key trends shaping and driving the global Respiratory Syncytial Virus (RSV) Prophylactic market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Respiratory Syncytial Virus (RSV) Prophylactic sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a of industry experts.

The Respiratory Syncytial Virus Prophylactic Market is Expected to Show Static Growth during the Forecast Period

The report estimates the global RSV prophylactic market to be worth $798.8m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% for the next eight years to reach $1,039.2m by 2019. In the current prophylactic market, Synagis (palivizumab) is the only US Food and Drug Administration (FDA) approved drug. Synagis was approved by the FDA in 1998, by the European Medicine Agency in 1999, and it was approved in Japan in 2002. The drug is set to expire in 2015 in the US. Synagis from MedImmune (AstraZeneca's biologics unit) is a humanized monoclonal antibody produced by recombinant deoxyribonucleic acid technology. Synagis is for the prevention of serious Lower Respiratory Tract (LRT) diseases caused by RSV in pediatric patients at high risk of RSV disease. The American Academy of Pediatrics Committee on Infectious Diseases (AAP) set the guidelines for the recommended dosage. The AAP guidelines in relaton to Synagis administration during RSV season that were set in 2003 were changed in July 2009. The major changes to the recommendations are: change in dosage pattern, risk groups and risk criteria. Therefore, the static growth in the market is primarily driven by the increase in the high risk group; infants with at least one risk factor associated with RSV as suggested in the changed guidelines. These changes are the major factors affecting the market during the forecast period.

The Respiratory Syncytial Virus Prophylactic Market has Significant Unmet Needs

There is significant unmet need in RSV prophylactic market. RSV is a highly contagious viral disease in infants and its prevention is a major concern. By the age of two to three years nearly all children will get infected with the virus. In the current market for the prevention of RSV, Synagis has a high treatment cost and repeated administration the drug to infants is the main concern. Recurrence has also been reported with Synagis which creates a high unmeet need. On average, children will get the infection at least once by the age of 24 months, and about half of children will experience two infections. Synagis has decreased this number but the recurrence of the infection is still present and this presents another unmet need in the market. Currently, there are no approved vaccines for RSV and there is a need for an ideal vaccine that will provide long lasting protection and that can be universally administered (not only to premature babies), for the prophylaxis of infants.

Weak Pipeline with all the Molecules in the Early Stage of Development

The current RSV pipeline is weak and all the molecules under development are in the early stages (Discover to Phase II). There are 21 molecules in the pipeline in various stages of development. Out of these, two molecules are in Phase II constituting 10%; three are in Phase I constituting 14% and 16 molecules are in the Preclinical and Discovery stages, constituting 76% of the total pipeline. There are 14 first-in-class molecules, 11 of which are vaccines. Vaccines are the dominating class in the pipeline followed by three monoclonal antibodies. Significant research is on-going for the development of vaccines and monoclonal antibodies; this area of immunoprophylaxis has shown considerable success.